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Paper
Views of the chairs of Scottish health boards on 
engagement with quality management and 
comparisons with English trusts 
ABSTRACT 
Objective: To describe the views of the chairs of Scottish health boards on the 
engagement of their boards with healthcare quality and to compare them with the 
views of the chairs of boards of English acute trusts. The focus of the Scottish 
Health Boards is on providing and commissioning care, while in England the acute 
trusts only provide care. 
Methods: We mailed a questionnaire, based on one used in England, to the 14 
health board chairs in NHS Scotland in January 2011. The results were compared 
with the results of a similar questionnaire given to English acute trust chairs in 
2009.
Results: Most chairs in Scotland (67%) prioritised oversight of quality. Quality is 
considered at most Board meetings (92%), taking over 20% of time for 69% of 
chairs. Most boards have local quality targets and feedback quality data to staff. 
Compared with England, boards in Scotland meet less frequently and focus less on 
quality (shorter discussions, less frequent data review, fewer local targets) but they 
are more optimistic about their board’s performance. 
Conclusions: Although most chairs of Scottish boards view quality as a priority, 
they pay less attention to it than chairs in England, possibly due to their additional 
role in commissioning care. 
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inTRoduCTion
The drive to improve the quality and safety of healthcare 
has increased in Scotland in recent years, as is evident by 
the implementation of a national patient safety programme 
(the Scottish Patient Safety Programme [SPSP]) and the 
publication of a quality strategy (NHS Scotland Healthcare 
Quality Strategy) in 2010.1,2 These have been accompanied 
by an increased emphasis on the important role of health 
boards in the leadership and governance of quality and 
performance of services. To support this, the US Institute 
for Healthcare Improvement, a partner of the SPSP, 
undertook ‘Boards on board’ sessions in Scotland in 
2011 and 2012, which aimed to ‘fully engage the 
governance leadership in quality and safety.3 
Boards in the NHS in the UK consist of the executive 
and non-executive directors responsible for the strategy, 
governance and performance of the healthcare body. 
Executive members generally include a chief executive 
and directors of finance, medicine and nursing. Non-
executive members include those with experience in 
relevant areas such as finance and corporate management. 
They may also include members to represent the local 
population, but there is no statutory requirement for 
this. Boards are chaired by a non-executive who has 
usually previously served as a member of the same or 
another NHS board. Non-executive members are 
selected by public appointment committees though the 
use of elections is currently being piloted in Scotland.4
Although England provides broadly similar healthcare 
services to Scotland, over the past two decades there 
has been an increasing divergence of policy with 
differences in funding, structures and governance 
arrangements.5,6 There are two key differences: First, in 
Scotland there is no structural separation between 
commissioning (purchasing) and providing care, with 14 
health boards responsible for both, whereas in England 
these functions have been separated between 
commissioners and providers since 1991; the second 
major difference, connected to the first, is that in England 
there is greater dependence on market forces between 
competing providers to improve the quality and 
productivity of services, whereas in Scotland these forces 
are not in action. 
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l It is beyond the scope of this paper to provide a detailed comparison of the population breakdown of 
the two countries and the impact that this might have 
on the provision of high quality care, but obvious 
differences include the relatively small Scottish 
population (5.3 million) and the spread of people 
across Scotland, from urban to remote and rural, 
including small island health boards. However, while this 
could lead to variation in how services are organised 
and delivered, the standards of safety, effectiveness and 
experience should be similar within the NHS in both 
countries.
Despite these differences, there have been similar recent 
policy initiatives in England to promote high quality 
healthcare (and to emphasise the role of boards in this) 
to those already described in Scotland. These include 
High Care Quality for All which aimed to put quality at 
the heart of the NHS and the introduction of Quality 
Accounts in 2010 which required providers to publish 
annual reports about the quality of their care alongside 
their financial accounting.7 This reflected the English 
National Quality Board’s view that ‘ultimately, it must be 
the board and leaders of provider organisations that 
take final and definitive responsibility for improvements, 
successful delivery, and equally failures, in the quality of 
care’.8 In recent months, the Francis Report examined 
these themes further and found that in one NHS 
Foundation Trust in particular there had been a 
disengagement from managerial and leadership 
responsibilities in relation to providing safe, high quality 
care.9 The report’s recommendations, which are relevant 
to the wider NHS in England, include greater 
accountability for senior managers and leaders in 
protecting the interests of patients. 
The role of boards in improving quality and safety of 
patient care is therefore recognised as important. 
However, there is very limited evidence about how 
effective boards are in undertaking this role – the only 
published studies are from the USA. They reported 
associations between the time spent by boards on 
quality issues and the quality of care their organisations 
provided.10,11 Whether or not such associations are 
causal is unclear.12 However, qualitative research supports 
the notion that if boards pay attention to quality, so will 
managers and, in turn, clinicians.13
It has been suggested following review of minutes from 
trust board meetings that while NHS trust boards in 
England have come a long way in the last ten years in 
terms of non-executive board members challenging 
Executive members, there is still considerable scope 
for improvement.14 A report covering commissioners 
and providers in England concluded that there is 
currently a gap between the best practice for boards 
and the reality. Examples include lack of alignment 
between strategic objectives and quality and safety 
issues, not enough time spent on quality and safety, 
and presentation of data that are not sufficiently 
robust.15
A survey of 1,000 board chairs of not-for-profit hospitals 
in the US confirmed similar findings, stating that quality 
was not always a top priority, few boards had formal 
training in quality and that there were large variations in 
board activity on quality between low and high 
performing organisations.16 This survey was repeated in 
2010 among the chairs of boards of acute trusts in the 
NHS in England.17 To date, there are no data to describe 
the role or the effectiveness of boards in improving 
quality in the NHS in Scotland. 
Our primary aim was to find out the views of board 
chairs in Scotland on the level of engagement in quality 
management of their boards (who are responsible not 
only for providing but also commissioning care). Secondly, 
we sought to compare this with the views of chairs of 
boards of acute trusts in England (who are responsible 
for providing but not commissioning care) and to 
determine whether the different responsibilities of these 
boards influence their prioritisation of quality issues. 
MeThodS
The questionnaire used in the USA16 was subsequently 
modified for use in England and further amended for use 
in Scotland. Changes from the version used in England 
were minimal to ensure comparability of the results.  The 
face and content validity of the Scottish version was 
initially tested with two executive board directors from 
two health boards and some minor alterations were 
made. The final version sought the views of the board 
chairs on five aspects:
A. Board training and expertise in quality
B. Quality of care as a priority
C. Influence of board and chief executive on quality  
 of care
D. Current performance and quality of services   
 provided 
E. Ways in which boards use data on quality
Quality was defined as encompassing safety, effectiveness 
and patient experience (humanity). Although quality 
management was not explicitly defined for the 
respondents, we expected it to cover the oversight of 
quality assessment and improvement. Questions about 
boards ‘spending time reviewing quality’ referred to 
activities such as considering the number of adverse 
incidents (including mortality) and the results of clinical 
audits of the effectiveness of care.
In terms of the questions about training in quality, we did 
not make any assumptions; we accepted the generally held 
view that, like training and education in general, it probably 
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enhances people’s understanding and competence. For 
board expertise in quality we expected that having a 
clinical background (defined as being a doctor, nurse or 
allied health professional) would be associated with 
knowledge and understanding of clinical aspects of quality 
(safety and effectiveness), though not necessarily an 
understanding of other organisational aspects.
The questionnaire was sent to the chairs of the 14 
territorial health boards in NHS Scotland in January 
2011. Non-responders were followed up and replacement 
copies of the questionnaire were provided on request. 
The data were analysed in an Excel spreadsheet (simple 
descriptive, comparative statistics) and, where applicable, 
the response categories previously used in the English 
survey were employed.
In the English study, chairs’ responses were compared 
with independent measures of performance in their 
healthcare organisation. This was not possible in the 
Scottish survey because the small number of boards 
precluded quantitative estimation of associations and 
because of the lack of directly comparable data, such as 
the Care Quality Commission indicators used in England. 
Data from some questions in the survey have not been 
included in the analyses, because either the equivalent 
English data were not available for comparison or there 
was insufficient information to make a confident 
interpretation. 
ReSulTS
A. Board training and expertise in quality
Chairs in Scotland had been members of their board for 
a considerable period of time (median six years), longer 
than in England (median four years). There was, however, 
little difference in the length of time as chair (about 
three years) (Table 1). The most noticeable difference 
was that in Scotland there were twice as many non-
executive directors (NEDs) as executive directors on 
the boards (mean 14 vs 6) whereas in England the two 
were similar in number. Scottish boards met less 
frequently than in England.
Although none of the Scottish chairs had a clinical 
background, most boards included at least one NED 
with clinical training (92%). This contrasted with the 
situation in England where only 42% of boards included 
clinically trained NEDs. Despite this, chairs in Scotland 
were no more likely to perceive that their NEDs had 
‘very substantial expertise’ in quality management. 
About half the Scottish boards provided formal training 
in quality management for their members (similar to 
England) although Scottish chairs were more likely to 
believe that additional training would be useful. 
Most Scottish chairs (85%) were familiar with the three 
key quality programmes in Scotland that relate to 
delivering safe, effective, person-centred care (the 
Healthcare Quality Strategy, the Better Together 
Programme and the SPSP). 
B. Quality as a priority
In Scotland most chairs considered quality of care to be 
the most important aspect for them to oversee (Table 
2). However, there was a sizable minority (33%) who 
gave priority to organisational and financial concerns. 
The principal difference from England was that in 
Scotland the emphasis was more likely to be on clinical 
effectiveness (33% vs 10%) than on safety (33% vs 63%). 
When considering safety, while boards in both countries 
were concerned about hospital-acquired infections 
(HAIs) (100% for both), in England medication errors 
were also a major issue (84% vs 50%).
Almost all Scottish boards review quality at every 
meeting, with the majority spending more than a fifth 
of their time on aspects of quality (as previously 
defined) (Table 2). In comparison, only 31% reported 
spending as much time on financial performance. In 
these regards, Scottish boards were similar to their 
Scotland
(n=13)
England
(n=132)
Length of service of chair
Median number of years 
on board (IQR) 
Median number of years 
as chair (IQR)
6 (5–8) 
3.5 (3–5)
4 (2–7)
3 (1–5)
Board composition
Mean number of 
executive directors (SD)
Mean number of non-
executive directors (SD)
6.0 (1.2)
14.0 (5.0)
5.7 (0.1)
6.3 (0.1)
Median number of times 
per year board meets 
(IQR) 7 (6–10) 12 (10–12)
Non-executive members 
with clinical background
Chair
Other non-executive 
members 
0 (0%)
12 (92%) 
5 (4%)
56 (42%)
Expertise and training in 
quality
‘Non-executive directors 
have very substantial 
expertise’
Formal training available
More training would be 
useful
4 (31%)
7 (54%)
13 (100%)
39 (30%)
55 (42%)1
109 (87%)2 
1Two chairs did not answer; 2Six chairs did not answer
IQR= interquartile range; SD= standard deviation
tABLE 1 Composition of the Board and expertise in 
quality management
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counterparts in England. All three dimensions of quality 
(effectiveness, safety, experience) were considered at 
least quarterly in both countries. The only difference was 
that fewer Scottish boards considered medication 
errors regularly (50% vs 84%). We did not distinguish 
whether any of these aspects of quality were part of 
local or national initiatives.
Most boards in Scotland set local targets, in addition to 
national ones, to improve quality and regularly reviewed 
a dashboard of quality indicators (77%) (Table 2). In 
England the proportion of boards setting local targets 
was higher across all quality dimensions, similarly a 
higher proportion of English boards (98%) set local 
targets. Most Scottish boards also had a quality 
subcommittee, similar to in England.
C. Influence of board and chief executive on 
quality of care 
The principal influence on quality at board level in 
Scotland was perceived by chairs to be equally divided 
between the chief executive (38%), executive directors 
(30%) and a board sub-committee on quality (23%) 
(Table 3). The relevant executive directors were doctors 
or nurses. A similar diversity was observed in England, 
where less influence was perceived to come from a 
board sub-committee on quality (5%) and more from 
the executive directors (43%). 
Despite the key contributions of the chief executive in 
many organisations, only two health boards (15%) 
believed that the chief executive is more engaged with 
quality than finance (Table 3). When evaluating individual 
performance, quality was deemed to be the most 
important topic  by only half the chairs, similar to the 
findings in England.
Scotland
(n=13)
England
(n=132)
Most important area for 
board oversight1
Organisation and finance  
Patient and public involvement
Quality of care
Clinical effectiveness
Safety
Patient experience
4 (33%)
0 (0%)
8 (67%)
4 (33%)
4 (33%)
0 (0%)
24 (18%)
7 (5%)
101 (77%)
13 (10%)
83 (63%)
5 (4%)
Issues reviewed at every 
meeting
Quality
Finance
12 (92%)
13 (100%)
129 (98%)
123 (93%)
More than 20% of meeting 
spent on issue
Quality
Finance
9 (69%)
4 (31%)
109 (83%)
50 (39%)
Dimensions of quality 
reviewed at least 
quarterly
Clinical effectiveness
Safety
Hospital-acquired 
infections
Medication errors
Patient experience
12 (92%)
13 (100%)
6 (50%)1
11 (85%)
125 (96%)2
132 (100%)
108 (84%)3
122 (92%)
Local targets in addition 
to national targets
Clinical effectiveness
Safety
Hospital-acquired 
infections
Medication errors
Patient experience 
8 (80%)3
8 (73%)
5 (50%)3
6 (60%)3
113 (86%)5
128 (97%)4
92 (70%)6
118 (94%)7
Quality dashboard/
scorecard reviewed 
regularly 10 (77%) 129 (98%)
Board has a quality sub-
committee 10 (77%) 107 (81%)
1One chair in Scotland did not respond; 2two non-
responses; 3three non-responses; 4four non-responses; 5six 
non-responses; 6eight non-responses; 7five non-responses; 
tABLE 2 Most important area for board oversight and 
board commitment to quality management (frequency and 
time spent in meetings and use of local targets) 
Scotland England
Principal influence on the 
board regarding quality:
Chief executive
Chair or other non-executive 
Director
Board’s quality sub-committee
Executive director
Medical director
Director of nursing
(n=13)
5 (38%)
1 (8%)
3 (23%)
4 (30%) 
2 (15%) 
2 (15%) 
(n=118)
52 (44%)
8 (7%)
6 (5%)
51 (43%)
20 (17%)
31 (26%)
Importance of quality 
management in chief 
executive’s role:
Greater engagement in 
quality than finance
(n=13)
2 (15%)
(n=132)
33 (25%)
Most important area in 
evaluating performance
Organisation and finance
Financial performance
Operations
Business strategy
Patient and public 
involvement
Quality of care
Clinical effectiveness
Safety
Patient experience
(n=12)
6 (50%)
2 (17%)
0 (0%)
4 (33%)
0 (0%)
6 (50%)
3 (25%)
3 (25%)
0 (0%)
(n=123)
52 (42%)
15 (12%)
4 (3%)
33 (27%)
0 (0%)
71 (58%)
13 (11%)
50 (41%)
8 (7%)
tABLE 3 Principal influence on the board regarding 
quality and importance of quality management in chief 
executive’s role 
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D. Current performance and quality of services 
provided 
Chairs felt that the quality of services their organisation 
provides were either the same as others or better (Table 
4). No one felt their performance was worse as regards 
patient experience and only one chair thought this was 
true for staff experience. Compared with England, 
Scottish chairs were less likely to be self-critical: 11% of 
English chairs thought their patients’ experience was 
worse or much worse than others. Similarly, 19% of 
English chairs thought that staff experience was worse or 
much worse, compared with 8% in Scotland. 
E. Ways in which boards use data on quality
The majority of chairs in Scotland reported that data are 
used to provide feedback to staff on clinical effectiveness, 
patient safety and patient experience (Table 5). This was 
also the case in England. Fewer Scottish boards used 
these data further to give awards for high performance 
and only a minority provided financial incentives for staff, 
similar to the position in England.
diSCuSSion
Main findings
The oversight of quality is considered to be the highest 
priority for the board by most Scottish chairs. To 
support this, chairs reported that quality appears on 
almost all board meeting agendas (often taking up more 
than 20% of the time) and most chairs report that their 
boards have set local quality targets in addition to those 
stipulated nationally. They also report that data on 
quality are regularly fed back to staff although there is 
little use of these data as a basis for rewards (recognition 
or financial) for performance. Overall, chairs believe that 
their board compares well with others, reporting that 
for both patient and staff experience they perform as 
average or better than average. None of the chairs 
perceive their Board’s performance as worse than 
average. The principal influencers of quality were either 
the chief executive, another executive director with a 
clinical background or a quality sub-committee of the 
board (chaired by a NED). Generally, the chair and non-
executive directors were not seen as influential. 
However, although chairs perceived that consideration 
of quality was their board’s priority, chief executives 
were seen as more engaged in finance (despite quality 
apparently being the most important consideration for 
half the chairs when evaluating a CEO’s performance).
Compared with England, Scottish chairs have been on 
their board, and in their position, for longer than their 
counterparts in England. Scottish Boards have a greater 
number of NEDs and are more likely to have a NED 
with a clinical background. However, Scottish Boards 
meet less frequently than those in England and focus less 
on quality, discuss it for a shorter time, review data less 
frequently and set fewer local targets. The priority when 
quality is discussed is effectiveness of care, whereas in 
England the priority is safety. As regards safety, most 
Scottish boards give greatest priority to HAIs, while in 
England medication errors are also prioritised. Even 
though Scottish boards review data less frequently than 
in England, chairs report greater use of data to provide 
feedback to staff. However, data on quality are less 
regularly used to provide rewards for staff than in 
England. Scottish chairs are more optimistic about their 
board’s performance on patient and staff experience 
than chairs in England.
Scotland
(n=13)
England
(n=126)
Patient experience
Much worse
Worse
About the same
Better
Much better
0 (0%)
0 (0%)
6 (46%)
4 (31%)
3 (23%)
1 (1%)
12 (10%)
44 (35%)
42(33%)
27 (21%)
Staff experience
Much worse
Worse
About the same
Better
Much better
0 (0%)
1 (8%)
7 (58%)
2 (17%)
2 (17%)
1 (1%)
23 (18%)
51 (39%)
31 (24%)
19 (15%)
tABLE 4 Chair’s view of their board/trust’s performance 
compared with others 
Scotland
(n=13)
England
(n=132)
Clinical effectiveness
Provide feedback to clinical 
staff
Awards/recognition for staff 
for high performance
Financial incentives to staff for 
high performance 
11 (92%)1
4 (33%)1
1 (8%)
78 (60%)1
62 (48%)3
6 (5%)2
Safety
Provide feedback to clinical staff
Awards/recognition for staff 
for high performance
Financial incentives to staff for 
high performance
12 (92%)
5 (38%)
1 (8%)
101 (78%)2
57 (44%)2
7 (5%)3
Patient experience
Provide feedback to clinical staff
Awards/recognition for staff 
for high performance
Financial incentives to staff for 
high performance
9 (69%)
4 (31%)
1 (8%)
91 (72%)4
55 (44%)5
6 (5%)6
1One chair did not respond; 2two chairs did not respond; 
3three chairs did not respond; 4six chairs did not respond; 
5seven chairs did not respond
tABLE 5 Ways in which data on quality used by boards 
on a regular basis
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l LimitationsThere are a number of limitations to this study. First, 
these are self-reported views of board chairs rather 
than objective evidence about the management of 
quality in their organisations. There is probably a 
tendency for chairs to overestimate the extent and 
effectiveness of quality management, as is evident by the 
finding that almost all considered their board’s 
performance was average or better than average. 
Second, there are only a small number of boards in 
Scotland so the extent of quantitative analysis is very 
limited. However, the high response rate means that the 
findings are representative of Scotland overall. 
Third, although the original questionnaire used in the 
USA was developed and tested using rigorous 
methodology and further limited testing was carried 
out in Scotland, there may have been different 
interpretations of some questions (face validity). For 
example, chairs were asked to consider their use of 
‘scorecards and goals in addition to those set nationally’. 
It is unclear if the responses consistently distinguished 
national from local. This was also the case for the 
reported use of a ‘scorecard’; a random review of 
board papers in Scotland suggests that these are not as 
widely used as reported. 
Fourth, we were unable to assess the standard of the 
activities that were reported. For example, how good 
the training, scorecards or expertise were. Similarly, we 
could not assess respondents’ understanding of terms 
used. Although quality was defined, other terms such as 
‘quality management’ and ‘clinical effectiveness’ were 
not.  It is possible (and even likely) that different 
interpretations were made. 
Interpretation of findings
In many ways, the views of the chairs of Scottish boards 
are similar to those of their counterparts, the chairs of 
acute trusts in England. As in England, Scottish chairs 
consider the management of quality a high priority, 
prioritising safety and effectiveness over experience 
(humanity of care) despite the latter being the principal 
area of concern for patients and being easily open to 
improvement.  Another similarity is the tendency in both 
countries for most chairs to consider the clinical 
services they provide as being either of average or 
better-than-average quality, which suggests that some 
chairs may be overestimating the quality of care that 
their organisation provides.
Although chairs report that their boards supplement 
national initiatives with local ones, there is less emphasis 
on the latter in Scotland, than appears to be the case in 
England. This suggests a more centralised, less devolved 
approach in Scotland which may reflect a wider difference 
in healthcare policy between the two countries. It might 
also reflect less need for local initiatives in Scotland, 
given that the entire country is similar in size to some 
English regions, so there is less of a separation between 
boards and central government.
Although Scottish boards have more NEDs than in 
England, and more have a clinical background, chairs are 
no more likely to perceive them as driving the quality 
agenda. Instead the leadership role is taken by the CEO, 
an executive director with a clinical background or a 
quality sub-committee. This is surprising, given that 
clinical safety and effectiveness tend to be prioritised 
over patient experience, the very aspects of quality that 
require clinical know-how. We might have expected 
NEDs in England to be more influential than those in 
Scotland, given the greater devolution of responsibility in 
England as reflected in the greater autonomy enjoyed by 
Foundation trusts. 
Similarly, despite the difference between the two 
countries in terms of market forces and competition, 
there was no more use of incentives to encourage 
quality improvements in England; in both countries 
information on the quality of services tended to be fed 
back to staff with little or no use of financial inducements. 
Implications 
Although this was a small study, it has raised questions 
about what more needs to be done to ensure that 
boards in Scotland are appropriately engaged in quality 
management. Chairs themselves identified the need for 
more training in quality management although, as with 
much training, there is little rigorous evidence of its 
effectiveness or cost-effectiveness, reflecting the 
methodological difficulties of evaluation. However, given 
the relatively small number of board members, the cost 
of training would be quite modest, particularly when set 
against the current level of resources devoted to post-
basic education and training by the NHS (about 5% of 
total healthcare expenditure). 
Some of the optimism about the quality of their services 
may be because of an underestimation of the levels of 
quality that can be achieved. Even allowing for estimates 
of the amount of time devoted to quality being 
overestimated by Scottish chairs, there is a need for 
some boards to consider whether they should give 
quality even greater attention and whether the priorities 
of executive members, including the CEO, should be 
realigned. Scottish boards appear to be less focused on 
quality than those in England, though this may reflect 
their dual role of commissioning and providing care, 
while English trusts focus entirely on the latter. 
In order for boards to sharpen their focus on quality, a 
deeper understanding is needed of what boards are 
actually doing; for example, what boards are discussing in 
the reported 20% of their meeting time spent on quality 
and which data they are using and how. In order for the 
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situation to be improved, it will be crucial to establish 
what boards understand about safety, effectiveness and 
patient experience – both how to measure these and 
how to improve them. These areas should be the subject 
of further work.
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